Serum creatinine (mg/dl) | |
unit | µmol/L mg/dL |
Serum concentrations of bilirubin (mg/dl) | |
unit | µmol/L mg/dL |
International normalized ratio for prothrombin time (INR) | |
Cause of Cirrhosis | Alcohol-related liver disease Cholestatic liver disease All other causes |
The Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure is sometime recommended in patients with portal hypertension, especially in those with variceal bleeding or ascites.
Although TIPS plus medical therapy appears superior to medical therapy alone for ascites; in some studies, it does not appear to improve survival, hospitalization rates or quality of life. A meta-analysis indicates improved transplant-free survival in cirrhotic patients with refractory ascites; however, hepatic encephalopathy was also more common in the TIPS group.
The outcome, when the TIPS procedure is recommended requires consideration, as some patients may realize worsening hepatic function and decreased survival.
Malinchoc's 2000 article in Hepatology, based upon 231 patients who underwent elective TIPS (173 for prevention of variceal rebleeding and 58 for refractory ascites), identified items that predict survival in patients undergoing elective TIPS.
The first item is a risk score R, which when R >1.8 indicates a median survival of 3 months or less. The following items are required to calculate the risk score R.
The formula for the Risk Score (R) is:
Patients with R >1.8 had median survival of 3 months or less.
Patients with R <=1.8 had median survival greater than 3 months.
After Risk Score is calculated to obtain the Probability Of Survival (POS) for a certain number of days after TIPS, we use the equation:
The table below shows the S (t) to be used for its respective number of survival days SD:
SD | S(t) |
---|---|
1 | 0.99 |
7 | 0.966 |
30 | 0.86 |
90 | 0.707 |
183 | 0.621 |
365 | 0.551 |
730 | 0.428 |
* Note: The model is likely to lose its accuracy the longer a patient is followed because other factors such as development of shunt stenosis, or a hepatocellular carcinoma may negatively impact survival.
References: